Chemotherapy of sarcomas: Optimization of existing drugs and new molecules;La chimiothérapie des sarcomes: Optimisation des substances existantes et nouvelles molécules

Cancer/Radiotherapie

Volumn 10, Issue 1-2, 2006, Pages 72-77

  Fayette, J ^a   Blay, J Y ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; Doxorubicin; Gemcitabine; Ifosfamide; Sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; IXABEPILONE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; RUBITECAN; SUNITINIB; TEMOZOLOMIDE; THROMBOSPONDIN 1; TRABECTEDIN;

ASTHENIA; CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; MYALGIA; NEUROPATHY; PRIORITY JOURNAL; REVIEW; SARCOMA;

EID: 33645279602     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2005.09.023     Document Type: Short Survey

References (52)

1. L.H. Baker, G.D. Demetri, and D.S. Mendelson A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS) (Abstract) Proc. Am. Soc. Clin. Oncol. 23 2005 819S
2. Bay JO, Fayette J, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Penel N, Peyrade F, Kerbrat P, Guillemet C, Ray-Coquard I, Blay JY. Docetaxel and gemcitabine association in 113 advanced soft tissues sarcomas: a retrospective analysis. CTOS 11th Annual Meeting, 2005.
3. R.S. Benjamin, S.S. Legha, S.R. Patel, and C. Nicaise Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience Cancer Chemother. Pharmacol. 31 1993 S174 S179
4. J.Y. Blay, A. Le Cesne, J. Verweij, M. Scurr, C. Seynaeve, and S. Bonvalot A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours Eur. J. Cancer 40 2004 1327 1331
5. G.T. Budd Management of angiosarcoma Curr. Oncol. Rep. 4 2002 515 519
6. J.M. Buesa, H.T. Mouridsen, A.T. van Oosterom, J. Verweij, T. Wagener, and W. Steward High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group Ann. Oncol. 2 1991 307 309
7. E.S. Casper, R.J. Waltzman, G.K. Schwartz, A. Sugarman, D. Pfister, and D. Ilson Phase II trial of paclitaxel in patients with soft-tissue sarcoma Cancer Invest. 16 1998 442 446
8. R. Chugh, R. Dunn, M.M. Zalupski, J.S. Biermann, V.K. Sondak, and J.R. Mace Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma J. Clin. Oncol. 23 2005 3597 3604
9. C.L. Corless, J.A. Fletcher, and M.C. Heinrich Biology of gastrointestinal stromal tumors J. Clin. Oncol. 22 2004 3813 3825
10. J.N. Cormier, and R.E. Pollock Soft tissue sarcomas CA Cancer J. Clin. 54 2004 94 109
11. G.D. Demetri, J. Desai, J.A. Fletcher, J.A. Morgan, C.D.M. Fletcher, A. Kazanovicz, A. Van Den Abbeele, C. Baum, R. Maki, and M.C. Heinrich SU11248, a multitargeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumour (GIST) Proc. Am. Soc. Clin. Oncol. 22 2004 3001 (Abstract)
12. J.H. Edmonson, L.M. Ryan, R.H. Blum, J.S. Brooks, M. Shiraki, and S. Frytak Randomized comparison of doxorubicin alone vs ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J. Clin. Oncol. 11 1993 1269 1275
13. F. Fata, E. O'Reilly, D. Ilson, D. Pfister, D. Leffel, and D.P. Kelsen Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face Cancer 86 1999 2034 2037
14. D.G. Gallup, J.A. Blessing, W. Andersen, and M.A. Morgan Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study Gynecol. Oncol. 89 2003 48 51
15. X. Garcia Del Muro, A. López Pousa, J. Buesa, J. Martin, I. Bover, P. Escudero, A. Casado, J.M. Trufero, and J. Maurel Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma (STS): a phase II trial of the Spanish Group for Research on Sarcomas (GEIS) Proc. Am. Soc. Clin. Oncol. 20 2001 1412 (Abstract)
16. R. Garcia-Carbonero, J.G. Supko, J. Manola, M.V. Seiden, D. Harmon, and D.P. Ryan Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J. Clin. Oncol. 22 2004 1480 1490
17. J.A. Gottlieb, R.S. Benjamin, L.H. Baker, R.M. O'Bryan, J.G. Sinkovics, B. Hoogstraten, J.M. Quagliana, S.E. Rivkin, G.P. Bodey Sr, V. Rodriguez, G.R. Blumenschein, J.H. Saiki, C. Coltman Jr, M.A. Burgess, P. Sullivan, T. Thigpen, R. Bottomley, S. Balcerzak, and T.E. Moon Role of DTIC (NSC-45388) in the chemotherapy of sarcomas Cancer Treat. Rep. 60 1976 199 203
18. J.A. Gottlieb, R.S. Benjamin, L.H. Baker, R.M. O'Bryan, J.G. Sinkovics, and B. Hoogstraten Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J. Clin. Oncol. 20 2002 2824 2831
19. I. Judson, J.A. Radford, M. Harris, J.Y. Blay, Q. van Hoesel, and A. le Cesne Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) vs doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 37 2001 870 877
20. W.J. Kostler, T. Brodowicz, Y. Attems, M. Hejna, S. Tomek, and G. Amann Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial Ann. Oncol. 12 2001 1281 1288
21. A. Le Cesne, E. Antoine, M. Spielmann, T. Le Chevalier, E. Brain, and C. Toussaint High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas J. Clin. Oncol. 13 1995 1600 1608
22. A. Le Cesne, J.Y. Blay, I. Judson, A. Van Oosterom, J. Verweij, and J. Radford Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J. Clin. Oncol. 23 2005 576 584
23. A. Le Cesne, I. Judson, D. Crowther, S. Rodenhuis, H.J. Keizer, and Q. Van Hoesel Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide vs high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group J. Clin. Oncol. 18 2000 2676 2684
24. K.M. Leu, L.J. Ostruszka, D. Shewach, M. Zalupski, V. Sondak, and J.S. Biermann Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma J. Clin. Oncol. 22 2004 1706 1712
25. K.Y. Look, A. Sandler, J.A. Blessing, J.A. Lucci 3rd, and P.G. Rose Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study Gynecol. Oncol. 92 2004 644 647
26. R.G. Maki, J.A. Fletcher, M.C. Heinrich, J.A. Morgan, S. George, J. Desai, K. Scheu, C.D. Fletcher, C. Baum, and G.D. Demetri Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) (Abstract) Proc. Am. Soc. Clin. Oncol. 23 2005 818S
27. O.S. Nielsen, P. Dombernowsky, H. Mouridsen, D. Crowther, J. Verweij, and J. Buesa High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group Br. J. Cancer 78 1998 1634 1639
28. R.M. O'Bryan, L.H. Baker, J.E. Gottlieb, S.E. Rivkin, S.P. Balcerzak, and G.N. Grumet Dose response evaluation of adriamycin in human neoplasia Cancer 39 1977 1940 1948
29. S. Okuno, J. Edmonson, M. Mahoney, J.C. Buckner, S. Frytak, and E. Galanis Phase II trial of gemcitabine in advanced sarcomas Cancer 94 2002 3225 3229
30. S. Okuno, W.J. Maples, M.R. Mahoney, T. Fitch, J. Stewart, and P.M. Fracasso Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium J. Clin. Oncol. 23 2005 3069 3073
31. S. Okuno, L.M. Ryan, J.H. Edmonson, D.A. Priebat, and R.H. Blum Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group Cancer 97 2003 1969 1973
32. A.S. Pappo, E. Lyden, P.P. Breitfeld, P. Houghton, D. Parham, S.S. Donaldson, W. Meyer, and W. Crist Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG) (Abstract) Proc. Am. Soc. Clin. Oncol. 21 2002 399a
33. S. Patel, N.E. Papadopoulos, M.A. Burgess, C. Plager, J.L. Beach, J.E. Jenkins, and R.S. Benjamin Phase 2 Study of 9-nitrocamptothecin (9-NC) in patients with advanced soft-tissue sarcomas (STS) (Abstract) Proc. Am. Soc. Clin. Oncol. 20 2001 292b
34. S.R. Patel, V. Gandhi, J. Jenkins, N. Papadopolous, M.A. Burgess, and C. Plager Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation J. Clin. Oncol. 19 2001 3483 3489
35. S.R. Patel, S. Vadhan-Raj, M.A. Burgess, C. Plager, N. Papadopolous, and J. Jenkins Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas Am. J. Clin. Oncol. 21 1998 317 321
36. S.R. Patel, S. Vadhan-Raj, N. Papadopolous, C. Plager, M.A. Burgess, and C. Hays High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence J. Clin. Oncol. 15 1997 2378 2384
37. G. Rosen, C. Forscher, S. Lowenbraun, F. Eilber, J. Eckardt, and C. Holmes Synovial sarcoma. Uniform response of metastases to high dose ifosfamide Cancer 73 1994 2506 2511
38. A. Santoro, T. Tursz, H. Mouridsen, J. Verweij, W. Steward, and R. Somers Doxorubicin vs CYVADIC vs doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J. Clin. Oncol. 13 1995 1537 1545
39. M.W. Saville, J. Lietzau, J.M. Pluda, I. Feuerstein, J. Odom, and W.H. Wilson Treatment of HIV-associated Kaposi's sarcoma with paclitaxel Lancet 346 1995 26 28
40. C.L. Sawyers Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor J. Clin. Oncol. 20 2002 3568 3569
41. G. Sutton, J.A. Blessing, and H. Ball Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study Gynecol. Oncol. 74 1999 346 349
42. L. Svancarova, J.Y. Blay, I.R. Judson, Q.G. van Hoesel, A.T. van Oosterom, and A. le Cesne Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 38 2002 556 559
43. S.M. Talbot, M.L. Keohan, M. Hesdorffer, R. Orrico, E. Bagiella, and A.B. Troxel A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma Cancer 98 2003 1942 1946
44. J.C. Trent, J. Beach, M.A. Burgess, N. Papadopolous, L.L. Chen, and R.S. Benjamin A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas Cancer 98 2003 2693 2699
45. M. Van Glabbeke, A.T. van Oosterom, J.W. Oosterhuis, H. Mouridsen, D. Crowther, and R. Somers Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J. Clin. Oncol. 17 1999 150 157
46. M. Van Glabbeke, J. Verweij, I. Judson, and O.S. Nielsen Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur. J. Cancer 38 2002 543 549
47. Q.G. van Hoesel, J. Verweij, G. Catimel, M. Clavel, P. Kerbrat, and A.T. van Oosterom Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group Ann. Oncol. 5 1994 539 542
48. A.T. van Oosterom, H.T. Mouridsen, O.S. Nielsen, P. Dombernowsky, K. Krzemieniecki, and I. Judson Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients Eur. J. Cancer 38 2002 2397 2406
49. J. Verweij, S.M. Lee, W. Ruka, J. Buesa, R. Coleman, and R. van Hoessel Randomized phase II study of docetaxel vs doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J. Clin. Oncol. 18 2000 2081 2086
50. P.J. Woll, I. Judson, S.M. Lee, S. Rodenhuis, O.S. Nielsen, and J.M. Buesa Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 35 1999 410 412
51. 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma J. Clin. Oncol. 23 2005 105 112
52. A. Yovine, M. Riofrio, J.Y. Blay, E. Brain, J. Alexandre, and C. Kahatt Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J. Clin. Oncol. 22 2004 890 899